LOS ANGELES — Action film icon Jet Li received the Gold Legend Award on Monday night at the 2026 Gold Gala, capping a distinguished career that has spanned more than four decades and bridged Eastern and Western cinema.

The annual gala, known for celebrating Asian and Asian-American contributions to entertainment, honored the 63-year-old martial artist and actor for his groundbreaking work in films that introduced millions of global audiences to Chinese martial arts traditions. The ceremony at the Beverly Hilton drew a star-studded crowd of industry figures, highlighting Li’s enduring influence on Hollywood and beyond.

Li, who rose to international fame in the 1990s with roles in “Once Upon a Time in China,” “Lethal Weapon 4” and the “Rush Hour” franchise, appeared visibly moved as he accepted the prestigious honor. His career has included more than 40 films, multiple blockbusters and a lasting legacy as one of the most recognizable martial arts stars since Bruce Lee.

The Gold Legend Award recognizes lifetime achievement and cultural impact. Previous recipients have included pioneers in film, music and television who have helped elevate Asian representation in global media. Organizers praised Li for his commitment to authentic fight choreography and his efforts to promote Chinese culture through cinema.

Born Li Lianjie in Beijing in 1963, Jet Li began training in wushu at age eight. He won multiple national championships in China before transitioning to acting in the early 1980s. His breakthrough came with the “Shaolin Temple” series, which became hugely popular across Asia and helped spark renewed interest in martial arts films.

Li’s Hollywood journey began in the late 1990s when he starred opposite Mel Gibson in “Lethal Weapon 4.” He quickly became a sought-after action performer, appearing in major productions including “The One,” “The Expendables” series and “The Forbidden Kingdom” alongside Jackie Chan. His ability to blend intense physical performance with dramatic depth earned him critical respect beyond the action genre.

Throughout his career, Li has balanced commercial success with personal values. He has been open about his Buddhist faith and interest in philosophy, often incorporating themes of inner peace and morality into his roles. In recent years, he has focused more on family and selective projects while dealing with health challenges, including a 2013 diagnosis of hyperthyroidism.

The Gold Gala appearance marked one of Li’s rare public outings in 2026. Attendees noted his gracious demeanor and willingness to share stories from his journey. The evening featured tributes from fellow actors and directors who credited Li with paving the way for greater Asian representation in Western films.

The event also served as a platform to discuss broader issues in the entertainment industry, including diversity, authentic storytelling and cross-cultural collaboration. Speakers highlighted how Li’s success helped open doors for subsequent generations of Asian talent in Hollywood.

Industry analysts view the award as timely recognition for an actor who helped globalize Chinese cinema during a pivotal period of cultural exchange. Li’s films have grossed hundreds of millions of dollars worldwide and influenced countless action sequences in modern blockbusters.

In addition to his film work, Li has engaged in philanthropy through his One Foundation, which focuses on disaster relief and children’s welfare in China. His humanitarian efforts have complemented his on-screen legacy, earning admiration from fans and peers alike.

The 2026 Gold Gala featured performances, fashion highlights and networking opportunities for emerging Asian talent. Several rising stars cited Li as an inspiration during panel discussions throughout the evening.

Li’s acceptance speech emphasized gratitude and the importance of cultural bridges. While specific quotes were not released publicly, those present described his remarks as humble and reflective of a career built on discipline and respect.

The award comes at a moment of renewed interest in classic martial arts cinema. Streaming platforms have revived many of Li’s earlier works, introducing them to younger audiences discovering the genre for the first time. This resurgence has sparked discussions about preserving fight choreography traditions while adapting them for contemporary viewers.

Hollywood’s relationship with Asian cinema has evolved significantly since Li first arrived in the United States. What began as supporting roles in American productions has grown into more substantial opportunities and creative control for Asian filmmakers and performers. Li’s career serves as an important chapter in that ongoing story.

Fans reacted enthusiastically on social media following the announcement, with many sharing favorite moments from his films and congratulating him on the well-deserved honor. The Gold Legend Award adds to a collection of accolades that includes lifetime achievement recognitions from various film festivals across Asia and Europe.

As Li enters what many consider the later stage of his career, the award provides an opportunity to reflect on his contributions while looking toward potential future projects. Industry insiders suggest he may take on more producing or mentorship roles, helping guide the next generation of action stars.

The Gold Gala 2026 itself reinforced themes of celebration and community. Organizers worked to create an inclusive environment that honored established legends while spotlighting emerging voices in entertainment. The balance between nostalgia and forward-looking optimism defined much of the evening’s tone.

For the broader Asian diaspora in Hollywood, events like the Gold Gala continue to play an important role in building networks and visibility. Li’s recognition serves as both a personal milestone and a collective achievement for those who have worked to expand representation.

Looking ahead, the entertainment industry watches closely as figures like Li transition into legacy roles. Their experiences provide valuable lessons about navigating cultural differences, maintaining artistic integrity and building sustainable careers in a competitive field.

The 2026 ceremony will likely be remembered as a highlight in Jet Li’s public journey — a moment that celebrated not only his on-screen accomplishments but also his off-screen dignity and commitment to meaningful causes.

As clips from the event circulate online, fans old and new continue to express appreciation for an actor who brought grace, power and authenticity to martial arts cinema for more than four decades. The Gold Legend Award stands as official recognition of a career that has left an indelible mark on global popular culture.

A massive, AI-driven structural rotation is reshaping emerging market equities, triggering record foreign capital flight from India toward East Asia’s tech manufacturing hubs. Global funds have dumped nearly $24 billion of Indian equities so far this year, chasing a relentless artificial intelligence (AI) boom that has already allowed Taiwan to overtake India as the world’s fifth-largest stock market. Now, South Korea looms as the next powerhouse poised to eclipse Mumbai, as major brokerages aggressively upgrade Seoul’s market targets while warning that India’s lack of direct tech hardware exposure will leave its foreign inflows muted for years.

Data compiled by Bloomberg shows Taiwan’s market capitalization climbed to $4.95 trillion as of Monday, while India’s value dropped to $4.92 trillion. Driven by a 49% rally this year in Taiwan Semiconductor Manufacturing Co. (TSMC), Taiwan now sits behind only the US, mainland China, Japan, and Hong Kong. Meanwhile, India’s key gauge is down 8%, heading for its first annual drop after a decade of gains, and its weight in the MSCI Emerging Markets index has collapsed from 19% last year to about 12%.

“Taiwan’s rising market capitalization is fundamentally a reflection of its heavy concentration in tech hardware, which is currently at the center of the AI investment cycle,” Yi Ping Liao, a fund manager at Franklin Templeton, was quoted as saying by Bloomberg. “Markets with limited exposure to tech hardware are increasingly being overshadowed by tech hardware–heavy markets such as Taiwan and Korea.”

Also Read | Taiwan overtakes India as world’s 5th largest stock market

The AI Supercycle and Its Winners

Taiwan’s ascent is, in large part, the story of one company. Taiwan Semiconductor Manufacturing Co. now accounts for about 42% of the benchmark index and its shares have rallied 49% this year as its semiconductors have captured a dominant position in the AI supply chain. New regulations are further cementing TSMC’s gravitational pull: Taiwan’s financial regulator last month raised the limit domestic funds can hold in a single stock to 25% of net assets, up from 10%, for listed companies whose index weighting exceeds 10%. Currently, only TSMC qualifies. JPMorgan Chase & Co. estimates the regulatory change could lure more than $6 billion of additional inflows into Taiwan.

South Korea is rapidly emerging as the next major beneficiary. Nomura has dramatically raised its 2026 KOSPI target to 10,000–11,000, up from a prior range of 7,500–8,000, citing what it calls a “commodity memory and high-bandwidth memory supercycle.” The brokerage expects AI-driven earnings to deliver 200% year-on-year growth for Korean corporates in 2026, followed by 29% in 2027. Korea’s exports from January through April 2026 hit a historical high of $306 billion, led by semiconductors.
Nomura sees the possibility of a self-reinforcing cycle taking hold in Korea: AI-driven export surpluses feeding into higher household incomes, stronger domestic consumption, potential won appreciation, and improved fiscal capacity — a virtuous loop that could sustain returns well beyond the current cycle.
Also Read | After stellar Q4, is a downgrade nightmare looming for India Inc in Q1?

India’s Structural Disadvantage

Against this backdrop, India’s position looks increasingly uncomfortable. Kotak Securities’ Sanjeev Prasad puts it plainly, flagging India’s “negative” exposure to the AI and semiconductor cycle, which, he warns, “may continue for another one to three years” as a primary reason foreign portfolio investors will stay away. Weak relative earnings growth in FY2027 and negative exposure to commodity cycles, particularly crude oil and natural gas, compound the problem. “The continued large FPI outflows from Indian equity markets reflect the steady deterioration of relative returns amid continued compression of relative earnings growth expectations,” Prasad said.

Elara Securities echoes the concern, pointing to the same trio of headwinds — earnings quality, AI-cycle exclusion, and commodity sensitivity — as structural rather than cyclical.

India’s weight in the MSCI emerging markets index has already fallen sharply, to about 12% from 19% last year, a retreat that reflects both the market’s underperformance and the reallocation of global capital toward AI-linked economies.

Domestically, the backdrop is equally challenging. Indian stocks have been hit by elevated valuations, a weakening rupee, surging energy costs that have stoked inflation concerns, and slowing corporate earnings growth, none of which is likely to attract the fast money now flooding into semiconductor-heavy markets.

Shares of renewable energy major Suzlon Energy could rally up to 31% from current market levels, experts say, after the company reported its March quarter earnings. The company posted a 6% year-on-year decline in consolidated net profit for the fourth quarter at Rs 1,114 crore, compared with Rs 1,182 crore in the same period last year.

Revenue from operations, however, rose sharply by 45% year-on-year to Rs 5,468 crore during the quarter. On a sequential basis, net profit jumped 150% from Rs 445 crore reported in the December quarter.

In today’s session, shares rose 3% to their day’s high of Rs 55.49 on the BSE.

Suzlon Energy shares: Buy, sell or hold?

Systematix has maintained its “Buy” rating on Suzlon Energy with a target price of Rs 71, implying an upside potential of 31.5%. The brokerage remains positive on the company due to its market leadership and its key role in driving wind energy capacity additions in India, supported by improving execution capabilities and increasing focus on EPC, hybrid and FDRE projects.

Systematix said Suzlon’s transition towards a DevCo-led integrated renewable energy platform, backed by a development pipeline of around 25 GW and a rising EPC mix, is likely to improve execution control, address industry bottlenecks and enhance customer stickiness. The brokerage has lowered its PAT estimates by 4% to factor in revised EPC mix assumptions, but still expects the company to deliver revenue, EBITDA and PBT CAGR of 21%, 28% and 34%, respectively, over FY26-FY28E.
Motilal Oswal has maintained its “Buy” rating on Suzlon Energy with a target price of Rs 65, implying an upside potential of 20%. The brokerage said key monitorables for the company include the pace of fresh order inflows, project deliveries and installations during FY27 and FY28, which will be crucial for sustaining the current growth trajectory.
It also highlighted that the EBITDA margin for the WTG segment remained flat sequentially at 13.7% in Q4FY26, lower than the stronger 15-16% levels reported in Q1 and Q2FY26. In addition, Motilal Oswal noted that the increasing contribution of the EPC business in the overall order mix could put some pressure on working capital going forward.
JM Financial has maintained its “Buy” rating on Suzlon Energy with a target price of Rs 65, implying an upside potential of 20.4%. The brokerage highlighted the company’s healthy order book of 5,892 MW as of May 2026, up from 5,025 MW in March 2025, with a diversified mix comprising 88% from the 3x MW series, 51% from commercial and industrial customers, 15% from PSU customers and 72% non-EPC orders.

The brokerage added that wind energy is gaining greater policy and industry attention amid rising peak power shortages, as wind generation is available during evening hours. It also noted that the ongoing Middle East crisis has indirectly increased the relevance of wind power, with merchant sales from wind portfolios currently generating exceptionally strong gains.

Contrarian view

Nuvama Institutional Equities downgraded Suzlon Energy shares to Hold and set a target price of Rs 55, implying an upside of just 3%. The brokerage believes Suzlon Energy remains well placed to benefit from the rising share of FDRE, RTC and hybrid tenders, along with increasing PSU-led project activity, supported by its strong exposure to the commercial and industrial and captive segments, which account for 51% of its order book.

However, it expects the domestic wind industry’s annual capacity additions to stabilise at 8–10 GW over the next two to three years as competition from solar and battery energy storage projects intensifies. Assuming Suzlon maintains a 30–35% market share, the brokerage estimates annual execution could level off at around 3–3.5 GW during FY27–28.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Indian equity markets have managed to sustain above the psychologically important 24,000 mark this week, supported by improving sentiment, steady earnings, and hopes of easing geopolitical tensions in West Asia. Market expert Sandip Sabharwal believes the recent rally has been aided by overly negative positioning among investors, creating room for a rebound despite lingering uncertainties.

Speaking to ET Now, Sabharwal said that structurally the market setup remains favourable because sentiment around India had turned excessively pessimistic over the past few weeks. According to him, that negativity itself has created a stronger base for equities to recover.

However, he cautioned that the sustainability of the rally will depend heavily on crude oil prices and developments surrounding the ongoing conflict in West Asia. While recent news flow hints at the possibility of some resolution, he noted that geopolitical situations remain highly volatile and unpredictable.

Sabharwal pointed out that the latest earnings season has been reasonably healthy, which provides downside protection to markets. At the same time, he believes the pace of the market’s upward movement will depend on how quickly geopolitical tensions ease. Instead of a runaway rally, he expects a more gradual and slightly volatile uptrend if uncertainty persists.

Chemical Stocks: Tactical Opportunity Rather Than Structural Revival

Chemical companies have emerged as strong performers after posting robust quarterly numbers. Stocks such as Sudarshan Chemical Industries have reported record topline growth and healthy operating margins, sparking optimism about a broader revival in the sector.
Sabharwal, however, sees the current rally more as a trading opportunity than the beginning of a long-term structural upcycle.
He explained that several chemical manufacturers benefited from a temporary mismatch between rising end-product prices and lower-cost raw material inventories carried earlier. This, in turn, led to a sharp improvement in profitability during the quarter.
According to him, the sector’s recent earnings rebound must also be viewed in the context of the extremely depressed profitability levels witnessed earlier. He stressed that the demand environment has not improved dramatically enough to justify expectations of a sustained multi-year uptrend.

Sabharwal added that many chemical companies expanded aggressively after the post-pandemic profit boom, resulting in an unfavourable global demand-supply balance. While select specialty chemicals may continue to perform well, he does not believe the broader sector is entering a durable long-term bull phase.

OMCs Remain a High-Risk Policy Bet
On oil marketing companies, Sabharwal maintained a cautious stance. Companies such as Indian Oil Corporation, Bharat Petroleum Corporation Limited and Hindustan Petroleum Corporation Limited remain highly sensitive to government policy decisions, making them difficult long-term investments from a shareholder perspective.

He noted that fuel price deregulation has effectively weakened, leaving profitability dependent on government intervention rather than market forces. In such an environment, investors are essentially betting on policy actions rather than business fundamentals.

Still, Sabharwal believes there could be trading opportunities if crude oil prices correct sharply following any diplomatic breakthrough in the Middle East. A significant fall in crude prices could lead to a strong recovery in profitability for OMCs, benefiting investors willing to take short-term exposure.

Rising Fuel Prices Could Trigger Broader Inflation Risks
Sabharwal also warned about the broader economic implications of elevated fuel prices. He highlighted that cost inflation has already started filtering through multiple sectors as companies face rising packaging, logistics, and raw material expenses.

Several companies across industries have reportedly announced price hikes ranging between 5% and 10% to offset cost pressures. Tyre manufacturers, in particular, have seen raw material costs rise sharply, further adding to inflationary stress.

According to Sabharwal, fuel prices have a multiplier effect across the economy because transportation costs influence virtually every segment. While food inflation remains relatively moderate for now, risks remain if weather disruptions linked to El Niño impact rainfall patterns.

He added that moderate inflation is not necessarily negative for corporate earnings because higher prices often support faster topline growth. However, the bigger question is whether companies will be able to protect margins while dealing with elevated input costs.

Sabharwal believes the inflation outlook will ultimately depend on how quickly geopolitical tensions ease, crude prices stabilise, and global shipping and logistics normalise.

Pharma Rally Continues, But Outlook Remains Mixed
Pharmaceutical stocks have also outperformed recently, with the sector gaining nearly 6% this month. Companies including Cipla and Sun Pharmaceutical Industries remain in focus as investors search for defensive opportunities amid global uncertainty.

Sabharwal described the sector’s earnings performance as mixed. While some companies delivered steady results, most failed to significantly outperform expectations. He also noted emerging profitability pressure in certain large pharmaceutical firms.

He pointed out that smaller companies linked to the CDMO theme have reported strong numbers, though he remains cautious due to concerns around cash flow quality in parts of the sector.

Overall, Sabharwal does not see pharma as a secular market-wide theme at present, suggesting that stock-specific opportunities may continue to outperform broader sector bets.

NEW YORK — Rockstar Games will begin marketing “Grand Theft Auto 6” this summer, parent company Take-Two Interactive confirmed Thursday, even as the highly anticipated title’s price remains undisclosed ahead of its scheduled Nov. 19 release.

Take-Two CEO Strauss Zelnick addressed the timing during an interview, pushing back against immediate expectations. “So the next few weeks I don’t think it’ll be summertime yet, but when it’s summertime, Rockstar expects to start marketing ‘GTA 6,’” he said.

The confirmation comes as speculation swirls around one of the most eagerly awaited video game releases in history. “GTA 6” is widely expected to be a massive commercial success, potentially breaking industry sales records upon launch.

Zelnick firmly reiterated the Nov. 19 launch date during Thursday’s earnings discussion. “I think reiterating November 19 as is a launch day today is probably a positive,” he noted, addressing recent rumors of possible delays or pre-order openings.

When asked whether a price announcement would accompany Take-Two’s quarterly earnings release, Zelnick gave a direct response. “No,” he said. “We never make marketing announcements in our analyst calls. Never ever ever.”

The absence of a price tag has not prevented Take-Two from issuing strong financial guidance for the fiscal year ahead. The company projected net revenue between $8 billion and $8.2 billion for the period running April 2026 through March 2027, representing approximately 20% growth over the previous year.

Zelnick explained how such projections are possible without a finalized price point. “So, whenever we put together our guidance, obviously based on our expectations regarding our pipeline, release schedule and pricing, and sometimes our expectations cannot be realized in the fullness of time,” he said. “That could be because the title is delayed, or pricing changes, or unit sales expectations change. But yes, of course, when we build our model, which is used to create guidance, it does have full assumptions in it. Even if we made assumptions, that doesn’t mean that they are set in stone.”

The upcoming marketing campaign is expected to be one of the largest in gaming history. Industry analysts anticipate a multi-month blitz featuring trailers, gameplay reveals, influencer partnerships and extensive social media engagement as Rockstar builds excitement for the title.

“GTA 6” marks the first mainline entry in the Grand Theft Auto series since 2013’s “GTA 5,” which has sold more than 200 million copies worldwide and generated billions in revenue across platforms. The new game is set in a reimagined Vice City inspired by modern-day Miami and is expected to push technical boundaries with its scale, storytelling and online features.

Take-Two reported solid fiscal fourth-quarter results alongside the forward-looking commentary. For the January-March period, the company posted GAAP net revenue of $1.68 billion and a net loss per share of 32 cents. Full-year net bookings reached $6.72 billion, up 19% from the previous year.

The company also highlighted the upcoming September release of “NBA 2K27” as another key title in its pipeline. However, all eyes remain firmly on “GTA 6” as the clear flagship for Take-Two’s growth ambitions.

Investors reacted positively to the earnings and commentary, with shares rising in after-hours trading. The confirmation of summer marketing provides a concrete timeline for what has been one of the most tightly guarded projects in entertainment.

The gaming community has been rife with rumors in recent weeks, including speculation about pre-order availability, potential price points above $70, and even minor delays. Take-Two’s statements appear designed to quell some of that speculation while maintaining strategic ambiguity around pricing and specific campaign details.

Rockstar Games has cultivated a reputation for meticulous development and surprise reveals. The studio’s marketing approach for previous titles has involved carefully timed trailers that generate massive online engagement and media coverage. A similar strategy is widely expected for “GTA 6.”

Analysts estimate the game could generate more than $2 billion in first-year sales, potentially making it one of the highest-grossing entertainment launches ever. Its success will be critical for Take-Two as it navigates a competitive landscape that includes major releases from competitors like Ubisoft, Electronic Arts and Microsoft’s Activision Blizzard.

The summer marketing push will likely begin in earnest during July or August, potentially coinciding with major gaming events or standalone digital showcases. Fans can expect the first official trailer or deep-dive gameplay footage to drop during this period.

Pricing remains a key unknown. While most major releases now carry a $70 suggested retail price, “GTA 6” could command a premium given its scope and the franchise’s cultural significance. Some analysts have speculated on a $70-$80 range for standard editions, with higher tiers for special or collector’s versions.

Take-Two’s ability to provide full-year guidance without revealing the price demonstrates the company’s confidence in its internal modeling and long-term pipeline. The fiscal 2027 outlook suggests management expects “GTA 6” to be a significant driver of growth.

Beyond the single-player campaign, “GTA Online” successor features are expected to play a major role in long-term monetization. The online component of “GTA 5” has proven extraordinarily durable, generating ongoing revenue years after launch.

As summer approaches, anticipation continues to build. The confirmation of a marketing start provides a focal point for fans and industry observers tracking every hint and leak about the game.

Take-Two’s disciplined approach to communication has served it well in the past, allowing Rockstar to maintain creative control and maximize impact when campaigns finally begin. This summer’s rollout will likely follow that proven playbook.

For now, gamers must wait a few more weeks for official summer to arrive and the marketing machine to kick into gear. When it does, “GTA 6” is expected to dominate entertainment conversations for months leading up to its November debut.

The Nov. 19 release date positions the game perfectly for holiday season sales, traditionally the strongest period for video game revenue. Strong pre-order numbers and launch-weekend performance could set new benchmarks for the industry.

As one of the most culturally significant entertainment franchises, “GTA 6” carries expectations that extend far beyond financial performance. Its storytelling, satire and open-world design have influenced generations of players and developers alike.

Take-Two’s latest update provides welcome clarity amid swirling rumors while preserving the mystery that has kept fans engaged for years. With marketing on the horizon and the release date locked in, the countdown to one of gaming’s biggest moments has officially begun.

SYDNEY — Shares in Fisher & Paykel Healthcare Corporation Ltd jumped more than 9% on Tuesday after the New Zealand medical device maker reported robust full-year results and reaffirmed confidence in its growth trajectory amid rising global demand for respiratory care products.

The stock climbed $2.52, or 9.15%, to close at $30.05 on the ASX and NZX, marking one of its strongest single-day gains in recent months. The rally reflected investor enthusiasm for the company’s performance in the year ended March 31, 2026, as well as optimism about its position in the expanding healthcare technology sector.

Fisher & Paykel, a leader in humidified respiratory care, sleep apnea treatment and surgical products, has benefited from sustained demand for its equipment in hospitals and home care settings worldwide. The company’s products, including high-flow nasal cannula systems and CPAP devices, have seen particular strength in North America and Europe.

Analysts highlighted the company’s ability to deliver margin expansion despite supply chain challenges and currency fluctuations. The results come after the company upgraded its fiscal 2026 guidance earlier in the year, projecting operating revenue of approximately NZ$2.30 billion and net profit after tax between NZ$450 million and NZ$470 million.

The strong share price reaction underscores Fisher & Paykel’s status as a market darling on the NZX and ASX. As one of New Zealand’s largest listed companies by market capitalization, its performance carries significant weight for the broader market and superannuation funds with heavy exposure to the healthcare sector.

Investors appear particularly encouraged by the company’s consistent innovation pipeline and growing presence in emerging markets. Fisher & Paykel has expanded its manufacturing footprint and invested in research and development to maintain its technological edge in non-invasive ventilation and airway management solutions.

The medical device sector has faced headwinds from inflation, logistics costs and regulatory pressures in recent years. Fisher & Paykel’s ability to navigate these challenges while delivering growth has set it apart from peers and supported premium valuations.

Company executives are scheduled to host an investor briefing following the results release, providing further details on strategic priorities for the coming year. Key focus areas are expected to include continued penetration in the hospital market, expansion of its homecare portfolio and opportunities in digital health integration.

The surge also comes against a backdrop of broader market caution, with many healthcare stocks facing pressure from potential policy changes and reimbursement uncertainties in key markets like the United States. Fisher & Paykel’s resilience highlights the defensive qualities of its recurring revenue business model.

Longer-term tailwinds for the company include aging populations in developed markets, rising prevalence of respiratory conditions linked to pollution and obesity, and increasing adoption of home-based care models post-pandemic. These structural trends support Fisher & Paykel’s medium-term growth targets.

Analysts have generally maintained positive outlooks on the stock. JPMorgan initiated coverage with an Overweight rating and a price target of NZ$37.50 earlier in 2026, citing strong organic growth potential and margin improvement opportunities. Other brokers have also raised targets following recent guidance upgrades.

The company’s focus on sustainability and product innovation has resonated with institutional investors. Recent product launches in high-flow therapy and advanced humidification systems have been well received by clinicians, supporting market share gains.

Geographically, North America remains the largest contributor to revenue, followed by Europe and Asia-Pacific. The company continues to invest in localized manufacturing and distribution to mitigate currency risks and improve service levels for customers.

Fisher & Paykel’s success reflects broader shifts in healthcare delivery. The emphasis on non-invasive solutions that reduce hospital stays aligns with cost-control pressures faced by health systems globally. Its products have played important roles in managing conditions ranging from sleep apnea to chronic obstructive pulmonary disease.

For retail investors on the ASX and NZX, the stock offers exposure to a high-quality growth company with strong cash flow characteristics. Dividend payouts have been attractive, providing income alongside capital appreciation potential.

The 9% gain on Tuesday helped recover some of the ground lost earlier in the year when the stock faced pressure from broader market rotation out of growth names. At current levels, the shares trade at a premium valuation, reflecting expectations of continued double-digit earnings growth.

Market watchers will closely monitor the upcoming investor briefing for any updates on capital allocation, including potential acquisitions or increased shareholder returns. The company has a track record of disciplined investment while maintaining a healthy balance sheet.

The rally also highlights the appeal of New Zealand-listed healthcare names amid global economic uncertainty. With stable governance, strong intellectual property and diversified revenue streams, Fisher & Paykel stands out as a quality compounder in the eyes of many fund managers.

Looking ahead, the company faces typical industry risks including competition, regulatory changes and currency volatility. However, its established brand, clinical evidence base and innovation track record provide a solid foundation for sustained performance.

Tuesday’s trading volume was elevated as investors repositioned portfolios following the results. The positive reaction suggests broad market agreement that Fisher & Paykel is well-placed to capitalize on long-term healthcare trends.

As one of Australasia’s most valuable healthcare companies, its performance influences sentiment toward the wider sector. The strong result may encourage renewed interest in other medical device and pharmaceutical names on both sides of the Tasman.

For the coming financial year, analysts expect continued revenue growth in the high single digits to low double digits, supported by new product cycles and geographic expansion. Margin improvement is also anticipated as supply chain normalization continues.

The Fisher & Paykel story exemplifies successful Kiwi innovation on the global stage. From humble beginnings in respiratory humidification, the company has grown into an international player with products used in thousands of hospitals worldwide.

Tuesday’s share price surge provides fresh momentum as the company enters its new financial year. With a clear strategy and strong execution, Fisher & Paykel Healthcare appears positioned to deliver further value for shareholders in the years ahead.

A company of Manulife Investment Management, John Hancock Investment Management serves investors through a unique multimanager approach, complementing our extensive in-house capabilities with an unrivaled network of specialized asset managers, backed by some of the most rigorous investment oversight in the industry. The result is a diverse lineup of time-tested investments from a premier asset manager with a heritage of financial stewardship. Note: This account is not managed or monitored by John Hancock Investment Management, and any messages sent via Seeking Alpha will not receive a response. For inquiries or communication, please use John Hancock Investment Management’s official channels.